The role of gaba-A receptor in the synergism between SSRI and antipsychotic in schizophrenia; implications for antipsychotic modes of actions

Current Medicinal Chemistry

Volumn 20, Issue 3, 2013, Pages 363-370

  Silver, Henry ^a   Einoch, Reef ^a   Youdim, Moussa ^a   Weinreb, Orly ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Antipsychotic drugs; GABA A receptor; Negative symptoms; Schizophrenia; Selective serotonin reuptake inhibitors

Indexed keywords

3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; 4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID A RECEPTOR BETA2; 4 AMINOBUTYRIC ACID A RECEPTOR BETA3; BRAIN DERIVED NEUROTROPHIC FACTOR; CLOZAPINE; FLUVOXAMINE; G PROTEIN COUPLED RECEPTOR; GLUTAMATE DECARBOXYLASE 67; HALOPERIDOL; MESSENGER RNA; METABOTROPIC RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; NEUROLEPTIC AGENT; PROTEIN KINASE C; RECEPTOR; SEROTONIN; SEROTONIN UPTAKE INHIBITOR;

ARTICLE; BEHAVIOR CHANGE; BRAIN LEVEL; COGNITIVE DEFECT; CYTOSOL; CYTOSOLIC FRACTION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; GENE EXPRESSION PROFILING; HUMAN; MOTOR ACTIVITY; NEGATIVE SYNDROME; NEUROTRANSMISSION; NONHUMAN; POSITIVE SYNDROME; PREFRONTAL CORTEX; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; RECEPTOR DOWN REGULATION; SCHIZOPHRENIA; SOCIAL BEHAVIOR; TREATMENT DURATION; WORKING MEMORY;

EID: 84877988478     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986713804870792     Document Type: Article

References (120)

1. Lewis, S.W.; Barnes, T.R.; Davies, L.; Murray, R.M.; Dunn, G.; Hayhurst, K.P.; Markwick, A.; Lloyd, H.; Jones, P.B., Schizophr Bull, 2006, 32, (4), 715-723.
2. Burton, S., Journal of psychopharmacology (Oxford, England), 2006, 20, (6 Suppl), 6-19.
3. Rummel, C.; Kissling, W.; Leucht, S., Cochrane database of systematic reviews (Online), 2006, (3), CD005581.
4. Silver, H.; Barash, I.; Aharon, N.; Kaplan, A.; Poyurovsky, M., Int Clin Psychopharmacol, 2000, 15, (5), 257-261.
5. Silver, H.; Nassar, A., Biol Psychiatry, 1992, 31, (7), 698-704.
6. Silver, H.; Shmugliakov, N., J Clin Psychopharmacol, 1998, 18, (3), 208-211.
7. Chaichan, W., Psychiatry and clinical neurosciences, 2004, 58, (4), 364-368.
8. Hiemke, C.; Peled, A.; Jabarin, M.; Hadjez, J.; Weigmann, H.; Hartter, S.; Modai, I.; Ritsner, M.; Silver, H., J Clin Psychopharmacol, 2002, 22, (5), 502-506.
9. Lammers, C.H.; Deuschle, M.; Weigmann, H.; Hartter, S.; Hiemke, C.; Heese, C.; Heuser, I., Pharmacopsychiatry, 1999, 32, (2), 76-77.
10. Silver, H.; Kaplan, A.; Jahjah, N., Am J Psychiatry, 1995, 152, (7), 1098.
11. Szegedi, A.; Anghelescu, I.; Wiesner, J.; Schlegel, S.; Weigmann, H.; Hartter, S.; Hiemke, C.; Wetzel, H., Pharmacopsychiatry, 1999, 32, (4), 148-153.
12. Silver, H.; Aharon, N.; Kaplan, A., Schizophr Bull, 2003, 29, (3), 541-546.
13. Brosen, K., Int Clin Psychopharmacol, 1998, 13 Suppl 5, S45-47.
14. Spina, E.; de Leon, J., Basic & clinical pharmacology & toxicology, 2007, 100, (1), 4-22.
15. Sproule, B.A.; Otton, S.V.; Cheung, S.W.; Zhong, X.H.; Romach, M.K.; Sellers, E.M., J Clin Psychopharmacol, 1997, 17, (2), 102-106.
16. Weigmann, H.; Gerek, S.; Zeisig, A.; Muller, M.; Hartter, S.; Hiemke, C., Therapeutic drug monitoring, 2001, 23, (4), 410-413.
17. Wetzel, H.; Anghelescu, I.; Szegedi, A.; Wiesner, J.; Weigmann, H.; Harter, S.; Hiemke, C., J Clin Psychopharmacol, 1998, 18, (1), 2-9.
18. Avenoso, A.; Spina, E.; Campo, G.; Facciola, G.; Ferlito, M.; Zuccaro, P.; Perucca, E.; Caputi, A.P., Pharmacol Res, 1997, 35, (4), 335-339.
19. Yasui-Furukori, N.; Kondo, T.; Mihara, K.; Inoue, Y.; Kaneko, S., Psychopharmacology (Berl), 2004, 171, (2), 223-227.
20. Baldessarini, R.J.; Cohen, B.M.; Teicher, M.H., Arch Gen Psychiatry, 1988, 45, (1), 79-91.
21. de Oliveira, I.R.; Dardennes, R.M.; Amorim, E.S.; Diquet, B.; de Sena, E.P.; Moreira, E.C.; de Castro-e-Silva, E.J.; Payan, C.; Fermanian, J.; Marcilio, C.; et al., Fundamental & clinical pharmacology, 1995, 9, (5), 488-502.
22. Volavka, J.; Cooper, T.B.; Czobor, P.; Lindenmayer, J.P.; Citrome, L.L.; Mohr, P.; Bark, N., J Clin Psychopharmacol, 2000, 20, (2), 252-256.
23. Poyurovsky, M.; Kurs, R.; Weizman, A., The Journal of clinical psychiatry, 2003, 64, (5), 611.
24. Goff, D.C.; Freudenreich, O.; Evins, A.E., CNS spectrums, 2001, 6, (11), 904, 907-911.
25. Stoll, A.L.; Haura, G., J Clin Psychopharmacol, 2000, 20, (4), 495-496.
26. Tsai, G.; Coyle, J.T., Annu Rev Pharmacol Toxicol, 2002, 42, 165-179.
27. Silver, H., CNS Drug Reviews, 2001, 7, (3), 283-304.
28. Siris, S.G., Br J Psychiatry Suppl, 1993, (22), 66-78.
29. Silver, H.; Kushnir, M.; Kaplan, A., Biol Psychiatry, 1996, 40, (7), 671-674.
30. Andreasen, N.C.; Nopoulos, P.; Schultz, S.; Miller, D.; Gupta, S.; Swayze, V.; Flaum, M., Acta Psychiatr Scand Suppl, 1994, 384, 51-59.
31. Silver, H.; David, D.; Kaplan, M.; Hadjez, J.; Tubi, N.; Darnel, A.; Calev, A.; Lerer, B., Schizophr Res, 1993, 10, (1), 67-75.
32. Silver, H., Int Clin Psychopharmacol, 2003, 18, (6), 305-313.
33. Danovich, L.; Weinreb, O.; Youdim, M.B.; Silver, H., Int J Neuropsychopharmacol, 2011, 14, (2), 143-155.
34. Chertkow, Y.; Weinreb, O.; Youdim, M.B.; Silver, H., Int J Neuropsychopharmacol, 2006, 9, (3), 287-296.
35. Danovich, L.; Weinreb, O.; Youdim, M.B.; Silver, H., Psychopharmacology (Berl), 2012, 220, (4), 763-770.
36. Luscher, B.; Fuchs, T.; Kilpatrick, C.L., Neuron, 2011, 70, (3), 385-409.
37. Chertkow, Y.; Weinreb, O.; Youdim, M.B.; Silver, H., J Neural Transm, 2007, 114, (11), 1443-1454.
38. Kronfol, Z.; Remick, D.G., Am J Psychiatry, 2000, 157, (5), 683-694.
39. Tian, J.; Chau, C.; Hales, T.G.; Kaufman, D.L., Journal of neuroimmunology, 1999, 96, (1), 21-28.
40. Avissar, S.; Roitman, G.; Schreiber, G., Cell Mol Neurobiol, 2001, 21, (6), 799-811.
41. Ilani, T.; Ben-Shachar, D.; Strous, R.D.; Mazor, M.; Sheinkman, A.; Kotler, M.; Fuchs, S., Proc Natl Acad Sci U S A, 2001, 98, (2), 625-628.
42. Gladkevich, A.; Kauffman, H.F.; Korf, J., Prog Neuropsychopharmacol Biol Psychiatry, 2004, 28, (3), 559-576.
43. Tang, Y.; Gilbert, D.L.; Glauser, T.A.; Hershey, A.D.; Sharp, F.R., Archives of neurology, 2005, 62, (2), 210-215.
44. Bowden, N.A.; Weidenhofer, J.; Scott, R.J.; Schall, U.; Todd, J.; Michie, P.T.; Tooney, P.A., Schizophr Res, 2006, 82, (2-3), 175-183.
45. Liew, C.C.; Ma, J.; Tang, H.C.; Zheng, R.; Dempsey, A.A., The Journal of laboratory and clinical medicine, 2006, 147, (3), 126-132.
46. Rothermundt, M.; Arolt, V.; Bayer, T.A., Brain, behavior, and immunity, 2001, 15, (4), 319-339.
47. Chertkow, Y.; Weinreb, O.; Youdim, M.B.; Silver, H., Prog Neuropsychopharmacol Biol Psychiatry, 2007, 31, (7), 1356-1362.
48. Dean, B.; Hussain, T.; Hayes, W.; Scarr, E.; Kitsoulis, S.; Hill, C.; Opeskin, K.; Copolov, D.L., J Neurochem, 1999, 72, (4), 1593-1599.
49. Toyooka, K.; Watanabe, Y.; Iritani, S.; Shimizu, E.; Iyo, M.; Nakamura, R.; Asama, K.; Makifuchi, T.; Kakita, A.; Takahashi, H.; Someya, T.; Nawa, H., Neuroscience research, 2003, 46, (3), 299-307.
50. Mirnics, K.; Middleton, F.A.; Stanwood, G.D.; Lewis, D.A.; Levitt, P., Mol Psychiatry, 2001, 6, (3), 293-301.
51. Broadbelt, K.; Ramprasaud, A.; Jones, L.B., Schizophr Res, 2006, 87, (1-3), 6-14.
52. Silver, H.; Susser, E.; Danovich, L.; Bilker, W.; Youdim, M.; Goldin, V.; Weinreb, O., Int J Neuropsychopharmacol, 2011, 14, (5), 573-584.
53. Reynolds, G.P.; Beasley, C.L., Journal of chemical neuroanatomy, 2001, 22, (1-2), 95-100.
54. Blum, P.B.; Mann, J.J., Int J Neuropsychopharmacol, 2002, 5, (2), 159-179.
55. Hashimoto, T.; Bazmi, H.H.; Mirnics, K.; Wu, Q.; Sampson, A.R.; Lewis, D.A., Am J Psychiatry, 2008, 165, (4), 479-489.
56. Kalkman, H.O.; Loetscher, E., Journal of Neural Transmission, 2003, 110, 803-812.
57. Volk, D.W.; Austin, M.C.; Pierri, J.N.; Sampson, A.R.; Lewis, D.A., Arch Gen Psychiatry, 2000, 57, (3), 237-245.
58. Benes, F.M.; Vincent, S.L.; Marie, A.; Khan, Y., Neuroscience, 1996, 75, (4), 1021-1031.
59. Deng, C.; Huang, X.F., Experimental brain research. Experimentelle Hirnforschung, 2006, 168, (4), 587-590.
60. Javitt, D.C., Current opinion in psychiatry, 2006, 19, (2), 151-157.
61. Shim, S.S.; Hammonds, M.D.; Kee, B.S., Eur Arch Psychiatry Clin Neurosci, 2008, 258, (1), 16-27.
62. Konradi, C.; Heckers, S., Pharmacol Ther, 2003, 97, (2), 153-179.
63. Weinberger, D.R.; Berman, K.F., Philos Trans R Soc Lond B Biol Sci, 1996, 351, (1346), 1495-1503.
64. Daskalakis, Z.J.; Fitzgerald, P.B.; Christensen, B.K., Brain research reviews, 2007, 56, (2), 427-442.
65. Eggan, S.M.; Hashimoto, T.; Lewis, D.A., Arch Gen Psychiatry, 2008, 65, (7), 772-784.
66. Silver, H.; Feldman, P.; Bilker, W.; Gur, R.C., Am J Psychiatry, 2003, 160, (10), 1809-1816.
67. Schmitt, A.; May, B.; Muller, B.; Jatzko, A.; Petroianu, G.; Braus, D.F.; Henn, F.A., Pharmacopsychiatry, 2003, 36, (6), 292-296.
68. Zhang, H.X.; Zhao, J.P.; Lv, L.X.; Li, W.Q.; Xu, L.; Ouyang, X.; Yuan, Z.Q.; Huang, J.S., Neurosci Lett, 2008, 438, (1), 1-5.
69. Fumagalli, F.; Frasca, A.; Racagni, G.; Riva, M.A., Mol Pharmacol, 2008, 73, (5), 1484-1490.
70. Tarazi, F.I.; Baldessarini, R.J.; Kula, N.S.; Zhang, K., J Pharmacol Exp Ther, 2003, 306, (3), 1145-1151.
71. Zink, M.; Schmitt, A.; May, B.; Muller, B.; Braus, D.F.; Henn, F.A., Pharmacopsychiatry, 2004, 37, (4), 171-174.
72. Zink, M.; Schmitt, A.; May, B.; Muller, B.; Demirakca, T.; Braus, D.F.; Henn, F.A., Schizophr Res, 2004, 66, (2-3), 151-157.
73. Feng, J.; Cai, X.; Zhao, J.; Yan, Z., J Neurosci, 2001, 21, (17), 6502-6511.
74. Pinna, G.; Costa, E.; Guidotti, A., Psychopharmacology (Berl), 2006, 186, (3), 362-372.
75. Silver, H.; Knoll, G.; Isakov, V.; Goodman, C.; Finkelstein, Y., J Psychiatr Res, 2005, 39, (6), 569-575.
76. Strous, R.D., Essential psychopharmacology, 2005, 6, (3), 141-147.
77. Tsai, G.E.; Yang, P.; Chang, Y.C.; Chong, M.Y., Biol Psychiatry, 2006, 59, (3), 230-234.
78. Heresco-Levy, U.; Javitt, D.C.; Ermilov, M.; Mordel, C.; Silipo, G.; Lichtenstein, M., Arch Gen Psychiatry, 1999, 56, (1), 29-36.
79. Lane, H.Y.; Huang, C.L.; Wu, P.L.; Liu, Y.C.; Chang, Y.C.; Lin, P.Y.; Chen, P.W.; Tsai, G., Biol Psychiatry, 2006, 60, (6), 645-649.
80. Menzies, L.; Ooi, C.; Kamath, S.; Suckling, J.; McKenna, P.; Fletcher, P.; Bullmore, E.; Stephenson, C., Arch Gen Psychiatry, 2007, 64, (2), 156-167.
81. Sawaguchi, T.; Matsumura, M.; Kubota, K., Behavioural brain research, 1988, 31, (2), 193-198.
82. Rao, S.G.; Williams, G.V.; Goldman-Rakic, P.S., J Neurosci, 2000, 20, (1), 485-494.
83. Lewis, D.A.; Volk, D.W.; Hashimoto, T., Psychopharmacology (Berl), 2004, 174, (1), 143-150.
84. Silver, H.; Shlomo, N.; Schwartz, M.; Hocherman, S., J Neuropsychiatry Clin Neurosci, 2002, 14, (1), 72-76.
85. Silver, H.; Feldman, P., J Neuropsychiatry Clin Neurosci, 2005, 17, (3), 391-398.
86. Silver, H.; Nassar, A.; Aharon, N.; Kaplan, A., Int Clin Psychopharmacol, 2003, 18, (2), 87-92.
87. Kucukibrahimoglu, E.; Saygin, M.Z.; Caliskan, M.; Kaplan, O.K.; Unsal, C.; Goren, M.Z., European journal of clinical pharmacology, 2009, 65, (6), 571-577.
88. Sanacora, G.; Mason, G.F.; Rothman, D.L.; Krystal, J.H., Am J Psychiatry, 2002, 159, (4), 663-665.
89. Bhagwagar, Z.; Wylezinska, M.; Taylor, M.; Jezzard, P.; Matthews, P.M.; Cowen, P.J., Am J Psychiatry, 2004, 161, (2), 368-370.
90. Goren, M.Z.; Kucukibrahimoglu, E.; Berkman, K.; Terzioglu, B., Neurochem Res, 2007, 32, (9), 1559-1565.
91. Arnsten, A.F., Psychopharmacology (Berl), 2009, 202, (1-3), 445-455.
92. Weinberger, D.R., Trends Neurosci, 1988, 11, (8), 367-370.
93. Birnbaum, S.G.; Yuan, P.X.; Wang, M.; Vijayraghavan, S.; Bloom, A.K.; Davis, D.J.; Gobeske, K.T.; Sweatt, J.D.; Manji, H.K.; Arnsten, A.F., Science, 2004, 306, (5697), 882-884.
94. Chertkow, Y.; Weinreb, O.; Youdim, M.B.; Silver, H., J Neural Transm, 2009, 116, (11), 1529-1541.
95. Carlsson, A.; Waters, N.; Holm-Waters, S.; Tedroff, J.; Nilsson, M.; Carlsson, M.L., Annu Rev Pharmacol Toxicol, 2001, 41, 237-260.
96. Brandon, N.J.; Delmas, P.; Kittler, J.T.; McDonald, B.J.; Sieghart, W.; Brown, D.A.; Smart, T.G.; Moss, S.J., J Biol Chem, 2000, 275, (49), 38856-38862.
97. Bhattacharyya, S.; Puri, S.; Miledi, R.; Panicker, M.M., Proc Natl Acad Sci U S A, 2002, 99, (22), 14470-14475.
98. Shelton, R.C.; Sanders-Bush, E.; Manier, D.H.; Lewis, D.A., Neuroscience, 2009, 158, (4), 1406-1415.
99. Song, M.; Messing, R.O., Cell Mol Life Sci, 2005, 62, (2), 119-127.
100. Arranz, B.; Rosel, P.; Sarro, S.; Ramirez, N.; Duenas, R.; Cano, R.; Maria Sanchez, J.; San, L., Psychiatry research, 2003, 118, (2), 165-174.
101. Meltzer, H.Y.; Li, Z.; Kaneda, Y.; Ichikawa, J., Prog Neuropsychopharmacol Biol Psychiatry, 2003, 27, (7), 1159-1172.
102. Rasmussen, H.; Ebdrup, B.H.; Erritzoe, D.; Aggernaes, B.; Oranje, B.; Kalbitzer, J.; Pinborg, L.H.; Baare, W.F.; Svarer, C.; Lublin, H.; Knudsen, G.M.; Glenthoj, B., Psychopharmacology (Berl), 2011, 213, (2-3), 583-592.
103. East, S.Z.; Burnet, P.W.; Kerwin, R.W.; Harrison, P.J., Schizophr Res, 2002, 57, (1), 15-26.
104. Wang, G.; Hu, C.; Jiang, T.; Luo, J.; Hu, J.; Ling, S.; Liu, M.; Xing, G., Schizophr Res, 2010, 121, (1-3), 160-171.
105. Govitrapong, P.; Chagkutip, J.; Turakitwanakan, W.; Srikiatkhachorn, A., Psychiatry research, 2000, 96, (1), 41-50.
106. Padin, J.F.; Rodriguez, M.A.; Dominguez, E.; Dopeso-Reyes, I.G.; Buceta, M.; Cano, E.; Sotelo, E.; Brea, J.; Caruncho, H.J.; Isabel Cadavid, M.; Castro, M.; Isabel Loza, M., Neuropharmacology, 2006, 51, (4), 923-932.
107. Moresco, R.M.; Colombo, C.; Fazio, F.; Bonfanti, A.; Lucignani, G.; Messa, C.; Gobbo, C.; Galli, L.; Del Sole, A.; Lucca, A.; Smeraldi, E., NeuroImage, 2000, 12, (4), 452-465.
108. Arranz, M.; Collier, D.; Sodhi, M.; Ball, D.; Roberts, G.; Price, J.; Sham, P.; Kerwin, R., Lancet, 1995, 346, (8970), 281-282.
109. Sen, S.; Duman, R.; Sanacora, G., Biol Psychiatry, 2008, 64, (6), 527-532.
110. Shimizu, E.; Hashimoto, K.; Watanabe, H.; Komatsu, N.; Okamura, N.; Koike, K.; Shinoda, N.; Nakazato, M.; Kumakiri, C.; Okada, S.; Iyo, M., Neurosci Lett, 2003, 351, (2), 111-114.
111. Piccinni, A.; Marazziti, D.; Catena, M.; Domenici, L.; Del Debbio, A.; Bianchi, C.; Mannari, C.; Martini, C.; Da Pozzo, E.; Schiavi, E.; Mariotti, A.; Roncaglia, I.; Palla, A.; Consoli, G.; Giovannini, L.; Massimetti, G.; Dell'Osso, L., Journal of affective disorders, 2008, 105, (1-3), 279-283.
112. Jindal, R.D.; Pillai, A.K.; Mahadik, S.P.; Eklund, K.; Montrose, D.M.; Keshavan, M.S., Schizophr Res, 2010, 119, (1-3), 47-51.
113. Angelucci, F.; Brene, S.; Mathe, A.A., Mol Psychiatry, 2005, 10, (4), 345-352.
114. Steiner, J.A.; Carneiro, A.M.; Blakely, R.D., Traffic (Copenhagen, Denmark), 2008, 9, (9), 1393-1402.
115. Ramamoorthy, S.; Giovanetti, E.; Qian, Y.; Blakely, R.D., J Biol Chem, 1998, 273, (4), 2458-2466.
116. Ramamoorthy, S.; Samuvel, D.J.; Buck, E.R.; Rudnick, G.; Jayanthi, L.D., J Biol Chem, 2007, 282, (16), 11639-11647.
117. Schubert, K.O.; Focking, M.; Prehn, J.H.; Cotter, D.R., Mol Psychiatry, 2012, 17, (7), 669-681.
118. Mathalon, D.H., Biol Psychiatry, 2012, 70, (7), 600-601.
119. Harvey, P.D.; Heaton, R.K.; Carpenter, W.T., Jr.; Green, M.F.; Gold, J.M.; Schoenbaum, M., Schizophr Res, 2012.
120. Silver, H.; Jahjah, N.; Kushnir, M., Schizophr Res, 1995, 16, (1), 77-79.